No Data
No Data
CSPC Pharmaceutical Gets China Nod for Clinical Trial of Cancer Drug
CSPC PHARMA (01093.HK) spent HKD 29.283 million on December 20 to repurchase 6.1 million shares.
On December 20, Geelonghui reported that CSPC PHARMA (01093.HK) announced that on December 20, 2024, it spent 29.283 million Hong Kong dollars to repurchase 6.1 million shares, with a repurchase price of 4.77-4.83 Hong Kong dollars per share.
Express News | CSPC Pharmaceutical - Approval Granted by China's Nmpa
Express News | CSPC Pharmaceutical - Semaglutide Long-Acting Injection (Syh9017) Obtains Clinical Trial Approval
CSPC Innovation Pharmaceutical (300765.SZ) subsidiary SYS6005 antibody-drug conjugate has received the notification of drug clinical trial approval.
CSPC Innovation Pharmaceutical (300765.SZ) announced that the company's holding subsidiary CSPC PHARMA Jushi Biopharmaceutical Co., Ltd...
The current cycle of Traditional Chinese Medicine materials is entering a downturn phase, and pharmaceutical companies may face a cost "turning point."
In the second half of 2024, the prices of Traditional Chinese Medicine materials are expected to decline overall; the semi-annual and third quarter reports of this year show that the gross margin of some Chinese Patent Medicine listed companies has significantly decreased, indicating a notable impact of the fluctuation in Traditional Chinese Medicine material prices on costs. However, with the retreat in Traditional Chinese Medicine material prices, production costs for companies will also decrease.
Willis88 : Junk stocks